Medical researchers in the UK and Australia have identified a new marker which could support the search for novel preventative and therapeutic treatments for dementia.
In an innovative new study, coordinated by Flinders University and University of Aberdeen, the researchers investigated the role of asymmetric dimethylarginine (ADMA), a blood marker associated with atherosclerosis and cardiovascular disease in epidemiological studies, on temporal changes in cognition in an established cohort of human aging (the 1936 Aberdeen Birth Cohort).
Unlike…
